- Home
- SPAI vs EQ Comparison
SPAI vs EQ Comparison
Compare SPAI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPAI
- EQ
- Stock Information
- Founded
- SPAI 2021
- EQ 2017
- Country
- SPAI United States
- EQ United States
- Employees
- SPAI N/A
- EQ N/A
- Industry
- SPAI Industrial Specialties
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SPAI Health Care
- EQ Health Care
- Exchange
- SPAI Nasdaq
- EQ Nasdaq
- Market Cap
- SPAI 27.1M
- EQ 24.8M
- IPO Year
- SPAI 2024
- EQ 2018
- Fundamental
- Price
- SPAI $4.47
- EQ $0.72
- Analyst Decision
- SPAI
- EQ Buy
- Analyst Count
- SPAI 0
- EQ 2
- Target Price
- SPAI N/A
- EQ $5.00
- AVG Volume (30 Days)
- SPAI 4.7M
- EQ 304.3K
- Earning Date
- SPAI 11-14-2024
- EQ 11-13-2024
- Dividend Yield
- SPAI N/A
- EQ N/A
- EPS Growth
- SPAI N/A
- EQ N/A
- EPS
- SPAI N/A
- EQ N/A
- Revenue
- SPAI $1,559,057.00
- EQ $45,914,000.00
- Revenue This Year
- SPAI N/A
- EQ N/A
- Revenue Next Year
- SPAI N/A
- EQ N/A
- P/E Ratio
- SPAI N/A
- EQ N/A
- Revenue Growth
- SPAI 35.50
- EQ 7.70
- 52 Week Low
- SPAI $1.56
- EQ $0.48
- 52 Week High
- SPAI $6.50
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- SPAI N/A
- EQ 40.86
- Support Level
- SPAI N/A
- EQ $0.66
- Resistance Level
- SPAI N/A
- EQ $0.77
- Average True Range (ATR)
- SPAI 0.00
- EQ 0.08
- MACD
- SPAI 0.00
- EQ -0.01
- Stochastic Oscillator
- SPAI 0.00
- EQ 26.09
About SPAI Safe Pro Group Inc. Common Stock
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Safe-Pro USA.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.